Sanara MedTech Q2 Revenue Misses, Swings to Loss; MiMedx Merger Looms

summarizeSummary

Sanara MedTech reported Q2 revenue of $28.1M, missing estimates, and swung to a loss. The pending MiMedx acquisition at $33.00 cash plus stock per share remains the key event for investors.

check_boxKey Events · Earnings and Guidance · SMTI

• Q2 Revenue Miss

  Revenue of $28.1M (+9% YoY) missed the $28.95M consensus, driven by soft tissue repair growth offset by a decline in bone fusion products.

• Swung to Loss

  Net loss from continuing operations was $0.4M vs. a $0.5M profit a year ago, pressured by higher SG&A, interest expense, and equity method losses.

• Adjusted EBITDA Improves

  Adjusted EBITDA rose to $5.0M from $4.7M, reflecting revenue growth and cost controls, but non-cash charges and interest costs eroded the bottom line.

• MiMedx Merger Pending

  The acquisition announced July 29 offers $33.00 cash and 0.4735 MiMedx shares per Sanara share. Shareholder vote and regulatory approvals are pending; closing expected by year-end.

auto_awesomeAnalysis · SMTI · Industrial Applications And Services

Sanara MedTech's Q2 revenue of $28.1M grew 9% year-over-year but fell short of the $28.95M consensus. The company swung to a $0.4M loss from continuing operations, driven by higher SG&A and interest costs. Adjusted EBITDA of $5.0M shows underlying operational improvement, but the miss and loss raise concerns about standalone execution. The pending acquisition by MiMedx for $33.00 cash and 0.4735 shares per Sanara share remains the dominant narrative — the merger is expected to close by year-end, subject to shareholder and regulatory approvals. The 10-Q also discloses $46.5M in long-term debt and $15.4M in cash, highlighting the financial pressure that likely motivated the sale.